Your browser doesn't support javascript.
loading
Both HIV-Infected and Uninfected Cells Express TRAILshort, Which Confers TRAIL Resistance upon Bystander Cells within the Microenvironment.
Nie, Zilin; Aboulnasr, Fatma; Natesampillai, Sekar; Burke, Stephen P; Krogman, Ashton; Bren, Gary D; Chung, Thomas D Y; Anderson, Jeff R; Smart, Michele K; Katzmann, David J; Rajagopalan, Govindarajan; Cummins, Nathan W; Badley, Andrew D.
Afiliación
  • Nie Z; HIV Immunology Laboratory, Mayo Clinic, Rochester, MN 55905.
  • Aboulnasr F; HIV Immunology Laboratory, Mayo Clinic, Rochester, MN 55905.
  • Natesampillai S; HIV Immunology Laboratory, Mayo Clinic, Rochester, MN 55905.
  • Burke SP; HIV Immunology Laboratory, Mayo Clinic, Rochester, MN 55905.
  • Krogman A; HIV Immunology Laboratory, Mayo Clinic, Rochester, MN 55905.
  • Bren GD; Department of Immunology, Mayo Clinic, Rochester, MN 55905.
  • Chung TDY; HIV Immunology Laboratory, Mayo Clinic, Rochester, MN 55905.
  • Anderson JR; Office of Translation to Practice, Mayo Clinic, Rochester, MN 55905.
  • Smart MK; Office of Translation to Practice, Mayo Clinic, Rochester, MN 55905.
  • Katzmann DJ; HIV Immunology Laboratory, Mayo Clinic, Rochester, MN 55905.
  • Rajagopalan G; Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905; and.
  • Cummins NW; Department of Immunology, Mayo Clinic, Rochester, MN 55905.
  • Badley AD; HIV Immunology Laboratory, Mayo Clinic, Rochester, MN 55905.
J Immunol ; 200(3): 1110-1123, 2018 02 01.
Article en En | MEDLINE | ID: mdl-29263214
ABSTRACT
TNF-related apoptosis-inducing ligand (TRAIL) was initially described to induce apoptosis of tumor cells and/or virally infected cells, although sparing normal cells, and has been implicated in the pathogenesis of HIV disease. We previously identified TRAILshort, a TRAIL splice variant, in HIV-infected patients and characterized it as being a dominant negative ligand to subvert TRAIL-mediated killing. Herein, using single-cell genomics we demonstrate that TRAILshort is produced by HIV-infected cells, as well as by uninfected bystander cells, and that the dominant stimulus which induces TRAILshort production are type I IFNs and TLR7, TLR8, and TLR9 agonists. TRAILshort has a short t1/2 by virtue of containing a PEST domain, which targets the protein toward the ubiquitin proteasome pathway for degradation. Further we show that TRAILshort binds preferentially to TRAIL receptors 1 and 2 with significantly reduced interaction with the decoy TRAIL receptors 3 and 4. Recombinant TRAILshort is sufficient to protect cells against TRAIL-induced killing, whereas immunodepletion of TRAILshort with a specific Ab restores TRAIL sensitivity. Importantly we show that TRAILshort is shed in microvesicles into the cellular microenvironment and therefore confers TRAIL resistance not only on the cell which produces it, but also upon neighboring bystander cells. These results establish a novel paradigm for understanding and overcoming TRAIL resistance, in particular how HIV-infected cells escape immune elimination by the TRAILTRAILshort receptor axis.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Linfocitos T CD4-Positivos / Infecciones por VIH / Isoformas de Proteínas / Ligando Inductor de Apoptosis Relacionado con TNF / Receptores del Ligando Inductor de Apoptosis Relacionado con TNF / Microambiente Celular Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Immunol Año: 2018 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Linfocitos T CD4-Positivos / Infecciones por VIH / Isoformas de Proteínas / Ligando Inductor de Apoptosis Relacionado con TNF / Receptores del Ligando Inductor de Apoptosis Relacionado con TNF / Microambiente Celular Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Immunol Año: 2018 Tipo del documento: Article